Precision BioSciences, Inc. is a clinical-stage gene editing company developing in vivo therapies using its proprietary ARCUS platform. The company focuses on genetic and infectious diseases, with lead programs including PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy. PBGENE-HBV is designed to eliminate covalently closed circular DNA and inactivate integrated viral DNA, while PBGENE-DMD is designed to excise specific exons of the dystrophin gene to restore muscle function. The ARCUS platform utilizes single-component nucleases delivered via adeno-associated viruses or lipid nanoparticles to perform gene insertion, elimination, and excision. The company was founded in 2006 by Jeff Smith and Derek Jantz following their discovery of the ARCUS technology at Duke University. Precision BioSciences previously operated in agricultural applications before spinning out its crop editing business as Elo Life Systems in December 2021. Current clinical trials are conducted in the United States, Hong Kong, New Zealand, Moldova, and the United Kingdom.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage precisionbiosciences.com
Sector Healthcare IR page investor.precisionbiosciences.com
Tags
gene editing, in vivo therapy, chronic hepatitis b, duchenne muscular dystrophy, nucleases, aav delivery, genetic diseases, clinical stage, ARCUS, PBGENE-HBV, PBGENE-DMD, PBGENE-3243, Elo Life Systems, ELIMINATE-B, FUNCTION-DMD
Press page —

Metrics

Valuation  
Market cap $ 271.957M
Market cap (USD) $ 271.957M
P/E -2.69
PEG —
P/BV 5.25
P/S 7.94
P/OCF -5.25
P/FCF -5.25
Dividend yield —
Turnover / mcap —
Returns  
ROE -61.5%
ROI -39.9%
ROIC -34.1%
Profit margin -133.4%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) —
Debt/Equity 24.3%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 65
Quality score -81.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Revenue 34.264M 68.696M 48.727M 25.098M 115.529M 24.285M 22.238M 10.883M
Net profit -45.724M 7.167M -61.319M -111.637M -30.602M -109.006M -92.877M -46.037M
Free cash flow -65.928M -58.695M -86.071M -49.072M -15.906M -92.417M -95.681M -66.001M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Share price 4.16 3.81 0.37 1.19 7.4 8.34 13.89 —
Price performance 12m 0.09 9.44 -0.69 -0.84 -0.11 -0.4 — —

Filed figures

Figure Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 523,000 965,000 10M 488,000 720,000 901,000 229,000 0.00
↳ YoY growth +84.5% +936.3% -95.1% +47.5% +25.1% -74.6% -100.0%
↳ 5y CAGR +11.5% -25.0%
Lease liabilities (USD) — — 11.6M 10.5M 6.64M 4.81M 8.86M 7.72M 6.4M
Cash and deposits (USD) 62.8M 103M 181M 89.8M 144M 190M 117M 85.9M 111M
Intangible assets (USD) — 1.47M 1.43M 1.37M 2.05M 1.35M 400,000 622,000 1.17M
Right-of-use assets (USD) — — 6.8M 6.41M 4.18M 2.97M 8.26M 7.09M 5.81M
Cash flow detail
Operating cash flow (USD) — -51.7M -71M -87.4M -10.9M -45.8M -84.1M -58.4M -65.8M
Purchases of property, plant and equipment (USD) — -14.3M -24.7M -5.03M -5.05M -3.32M -1.96M -250,000 -85,000
Change in receivables (cash effect) (USD) — -523,000 -441,000 -9.04M 9.51M -232,000 -181,000 672,000 229,000
Change in payables (cash effect) (USD) — -673,000 667,000 -1.46M 867,000 153,000 1.51M -2.1M -737,000
Interest paid (cash effect) (USD) — — — — -68,000 -824,000 -2.02M -1.74M -1.36M
Income taxes paid (cash effect) (USD) — — — — — — — — 0.00
Share-based compensation (USD) — 2.45M 8.94M 13.8M 16.5M 19.2M 14M 12.6M 10.2M
Operating cash flow before change in receivables (USD) — -51.2M -70.6M -78.4M -20.4M -45.5M -83.9M -59.1M -66.1M
Free cash flow (OCF - PPE - intangibles) (USD) — -66M -95.7M -92.4M -15.9M -49.1M -86.1M -58.7M -65.9M
Income detail
Research and development expense (USD) — 45.1M 82.4M 98.1M 115M 83.9M 53.4M 59.6M 54.2M
↳ 5y CAGR +3.4% -6.3% -11.2%
Reported Apr 29, 2019 Mar 10, 2020 May 15, 2020 Mar 18, 2021 Mar 9, 2023 Mar 9, 2023 Mar 27, 2024 Mar 26, 2025 Mar 12, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Precision BioSciences, Inc. — Other Events Bull 0 Bear 5 Financing

As previously reported, on November 5, 2026, Precision BioSciences, Inc. (the “Company”) entered into an underwriting agreement relating to the issuance and sale by the Company of 10,235,077 shares of its common stock, $0.000005 par value per share (the “Common Stock”), at a price of $7.75 per share and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase up to 5,893,964 shares of its Common Stock at a price of $7.749995 per pre-funded warrant (the “Offering”). The Company expects net proceeds from the Offering in addition to existing cash and cash equivalents, continued fiscal and operating discipline, and availability of its at-the-market facility will provide sufficient cash runway into the fourth quarter of 2029. Based on its expected cash runway, the Company projects it is sufficiently capitalized to fund both PBGENE-HBV and PBGENE-DMD clinical programs through key next stage inflection points.

DURHAM, N.C.—November 5, 2026 – Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the pricing of an underwritten offering of 10,235,077 shares of its common stock at a price of $7.75 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 5,893,964 shares of its common stock at a price of $7.749995 per pre-funded warrant, which represents the per share offering price for the shares of common stock less the $0.000005 per share exercise price for each pre-funded warrant. The gross proceeds to Precision from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be approximately $125 million. The deal includes participation from new and existing investors, including First Light Asset Management, MPM BioImpact, Bleichroeder LP, Lynx1 Capital Management, Readout Capital, Aberdeen Investments, Driehaus Capital Management, as well as other leading life sciences investors.

- Phase 1 ELIMINATE-B study successful, PBGENE-HBV Program Advancing to Phase 2-

- PBGENE-HBV achieves target product profile at 0.4 mg/kg dose-

- PBGENE-HBV achieved pgRNA loss to undetectable in 100% of evaluable patients at expected go-forward dose of 0.4 mg/kg; Durable and ongoing pgRNA loss in 100% of patients with ≥6 months of follow-up -

- In hard-to-treat patient population: HBeAg-positive patient achieved a 100% pgRNA loss to undetectable from a baseline of 3.7-log copies/mL at 0.4 mg/kg dose, patient’s pgRNA remained undetectable at data cut-off -

- Reproducible liver biopsy findings: PBGENE-HBV demonstrated a 1-log and 1.5-log reduction in cccDNA at 0.4 mg/kg the expected go forward dose across multiple patients -

- Treatment effect observed in 100% of evaluable patients as measured by HBsAg reduction -

- PBGENE-HBV demonstrated a well-characterized and manageable safety profile across 59 administrations in 25 patients, with no dose-limiting toxicities -

- Company to host investor and KOL webcast on Monday, November 9, 2026, at 8:00 a.m. ET presenting the late-breaking AASLD Phase 1 data -

DURHAM, N.C., November 5, 2026 -- Precision BioSciences, Inc.

Prompts

Precision BioSciences, Inc. (ticker DTIL), listed in United States.

ETFs Holding Precision BioSciences, Inc.

ETF Weight in ETF Shares Market value As of
AVSC 0.01% 37,053 $ 269.746K Nov 16, 2026
DXUV 0.00% 8,460 $ 68.018K Nov 12, 2026
DFAS 0.00% 34,093 $ 274.108K Nov 12, 2026
DFAU 0.00% 2,884 $ 23.187K Nov 12, 2026
DFAC 0.00% 5,826 $ 46.841K Nov 12, 2026
DCOR 0.00% 2,947 $ 23.694K Nov 12, 2026